Previous 10 | Next 10 |
Soligenix (NASDAQ: SNGX ): Q2 GAAP EPS of -$0.12 beats by $0.02 . More news on: Soligenix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PRINCETON, N.J. , Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its r...
Soligenix ( SNGX ) has a wide pipeline with late-stage candidates in the PDT treatment for various health problems, including Cutaneous T-Cell Lymphoma ((CTCL)), Oral Mucositis, Pediatric Crohn's Disease, and a vaccine candidate for ricin. Unfortunately, the company hasn't managed to bring any...
PRINCETON, N.J. , July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that ...
Medley Management (NYSE: MDLY ) +35% as Sierra, Medley Capital, Medley Management amend merger deals . More news on: Medley Management Inc., Sintx Technologies, Inc., NovaBay Pharmaceuticals, Inc., Stocks on the move, Read more ...
The European Patent Office has issued two patents to Soligenix (NASDAQ: SNGX ), both titled "Topically Active Steroids for use in Radiation and Chemotherapeutics Injury" with the latest issuing October 24, 2018, following the expiration of the objection period as of July 24, 2019. More n...
PRINCETON, N.J. , July 29, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the E...
PRINCETON, N.J. , July 8, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced t...
PRINCETON, N.J. , June 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that ...
Soligenix (NASDAQ: SNGX ) will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of ~$600,000 over 3 years. More news on: Soligenix, Inc., Healthcare stocks news, Read more .....
News, Short Squeeze, Breakout and More Instantly...
NEW YORK and PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is making significant strides in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...